ClinicalTrials.gg
Not yet recruitingNCT07595393Updated May 19, 2026

A Dose-Finding Study of Amogammadex Sodium for Reversing Vecuronium and Rocuronium-Induced Neuromuscular Blockade

A Phase 2 interventional study of Rocuronium (0.6mg/kg) and vecuronium bromide (0.1mg/kg) in Reversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery and Reversing Rocuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery, sponsored by Amckaus PTY LTD.. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Amckaus PTY LTD. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Background context: Amogammadex sodium has completed Phase I-III clinical studies in China for reversal of rocuronium-induced blockade. No clinical studies have yet been conducted for vecuronium-induced blockade. Therefore, this dose-finding study in an Australian population is intended to support further Phase III trials in European and American populations for reversal of both rocuronium- and vecuronium-induced neuromuscular blockade.

The goal of this clinical trial is to explore how well different doses of amogammadex sodium work to reverse neuromuscular blockade caused by rocuronium or vecuronium during surgery, and to learn about its safety. The main questions it aims to answer are:

  • How quickly and effectively does amogammadex sodium restore muscle strength after moderate or deep neuromuscular blockade?
  • What medical problems do participants have when receiving amogammadex sodium?

Researchers will compare different doses of amogammadex sodium to see which works best. All participants will receive amogammadex sodium, but at different dose levels depending on when they join the study.

Participants will:

  • Undergo screening up to 28 days before surgery to confirm eligibility
  • Receive amogammadex sodium at the end of surgery to reverse the effects of the muscle relaxant
  • Stay in the study for follow-up visits up to 7 days after surgery.
02

Conditions studied

  • Reversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery
  • Reversing Rocuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery

Keywords

  • Amogammadex sodium
  • neuromuscular blockade
  • Adamgammadex sodium
  • rocuronium bromide
  • vecuronium bromide
03

In context

Lead sponsor

Amckaus PTY LTD. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants should be willing to participate in the clinical study; the participants should fully understand and know this study and sign an form; the participants should be willing to follow and be able to complete all study procedures.
  2. Male or female, 18 ≤ age ≤ 60.
  3. Participant with the grade of American Society of Anaesthesiologists (ASA) physical status classification 1-2.
  4. Participants who are scheduled to undergo approximately 2-hour surgery under TIVA with endotracheal intubation, and for whom vecuronium or rocuronium bromide is planned as the sole neuromuscular blocking agent.
  5. (BMI) between 18 and 32 kg/m2 (both exclusive), and weight ≥ 50 kg for males and ≥ 45 kg for females.
  6. Willingness to use adequate (abstinence is acceptable if it aligns with lifestyle) and refrain from pregnancy, impregnating a partner, or donating sperm/ova from screening until 3 months after study completion. Females of nonchildbearing potential are exempt.

1)For females of : an adequate method of contraception is defined as the use of a condom by the male partner combined with the use of a highly effective method of contraception, either be sexually inactive (abstinent) for 28 days prior to the first dose and throughout the study, or be using one of the following acceptable birth control methods:

  1. Intrauterine device in place for at least 3 months prior to dosing with a barrier method (condom or diaphragm) and spermicide (if available) throughout the study
  2. Double barrier methods (e.g., condom and diaphragm) with spermicide (if available) for at least 28 days prior to dosing and throughout the study
  3. Surgical sterilization of the partner (vasectomy for 6 months minimum) with a barrier method (e.g., condom or diaphragm) and spermicide (if available) throughout the study.
  4. Bilateral tubal occlusion (e.g. Essure-non-surgical sterility procedure and Bilateral tubal ligation), and/or a vasectomized partner with documented azoospermia 90 days after procedure, if that partner is the sole sexual partner.

    2)For males: An adequate method of contraception is defined as use of a condom combined with the use of a highly effective method of contraception by the female partner of childbearing potential. Non-sterilized males with a female partner of childbearing potential must agree to use a double barrier method of birth control until five half-lives plus 90 days after the administration of the study drug.

    7.Female participants must be non-pregnant (confirmed by a negative serum at screening and urine pregnancy test on Day -1), non-lactating, or be of nonchildbearing potential (females who have been [defined as 24 months of amenorrhea in the absence of other biological cause] or are surgically sterile [hysterectomy or bilateral oophorectomy or bilateral complete salpingectomy]).

Exclusion criteria

Exclusion criteria:

  1. Known or expected difficult intubation due to anatomical deformities
  2. Known or suspected neuromuscular diseases, anatomical abnormality or neurological injury history that may affect neuromuscular transmission.
  3. History or manifestation of disease that, in the opinion of the investigator, renders the participant unsuitable for the study, including but not limited to nervous system, cardiovascular, blood, lymphatic, immune, kidney, liver, gastrointestinal, respiratory, metabolic, and musculoskeletal disorders.
  4. Participants with abnormal blood pressure not satisfactorily controlled (systolic blood pressure >160 mmHg or \< 90 mmHg, diastolic blood pressure > 100 mmHg or \< 60 mmHg). For subjects with systolic blood pressure ≥ 140 mmHg and ≤ 160 mmHg or diastolic blood pressure ≥ 90 mmHg and ≤ 100 mmHg and a history of well-controlled blood pressure, and no definite discomfort symptoms, the determination of clinical significance will be made at investigator discretion.
  5. Known heart failure or other serious cardiovascular diseases with (NYHA) functional class III or IV; with abnormal , interval (using Fridericia's formula) male > 450 ms, female > 470 ms, which is judged to have clinical significance by the investigators; with resting heart rate \< 60 bpm or > 100 bpm, which is judged to have clinical significance by the investigators.
  6. History of (HIV); or positive results at screening for HIV antibody/antigen (HIV Ab/Ag)
  7. Hepatic insufficiency or known liver disease:

    1. (ALT) or aspartate aminotransferase (AST) > 2.0 × (ULN);
    2. Known liver disease, such as acute hepatitis, chronic hepatitis ( positive with liver function abnormalities meeting the above criterion a, anti- positive), liver cirrhosis, etc., deemed by the investigator as inappropriate for study inclusion.
  8. kidney function impairment: Serum creatinine (Cr) >1.5 × ULN or having previously known severe kidney diseases or Estimated (eGFR) (CKD-EPI 2021 formula) \< 60 ml/(min·1.73m²) or renal insufficiency.
  9. Participants who had hereditary haemorrhagic diseases, coagulation disease, or non-traumatic bleeding history (bleeding that requires treatment), and thromboembolism; and currently have a risk of haemorrhage (including coagulation disease, thrombocytopenia [ count \< 100×109/L], thrombin original international standardized ratio > 1.5 or on a routine anticoagulation therapy).
  10. Participants known or suspected to have malignant hyperthermia or with family history; febrile illness defined as a body temperature above 37.5℃ within 7 days before administration.
  11. Systemic allergic reactions caused by any known reasons, including food allergy and allergy to animals; participants known or suspected to be allergic to cyclodextrin including sugammadex, anesthetics, muscle relaxants and other drugs used in general anesthesia; participants known to be allergic to gel electrodes.
  12. Participants who have taken fusidic acid and/or toremifene citrate within 24 hours prior to or scheduled within 24 hours after the study drug administration. Participants receiving drugs known to affect muscle relaxants within 24 hours before or during surgery (e.g., anticonvulsants, aminoglycoside antibiotics, magnesium salts [Mg2+]) except for supplements to maintain physiological levels.
  13. Participants with suspected alcohol or drug abuse;
  14. Participation in strenuous activity (e.g., heavy lifting, strenuous running, competitive sports such as basketball, football, and singles tennis, mountain climbing, rowing machine training, etc) within 48 hours prior to dosing (Day 1).
  15. Anatomical deformities on upper extremities that cannot perform monitoring mentioned in the protocol: non-invasive blood pressure monitor, ECG, pulse oximetry, end-tidal capnography and neuromuscular monitoring.
  16. Participants who participated in other clinical trials within 3 months before the administration.
  17. Female participants who are pregnant or breastfeeding, who have a positive serum or urine pregnancy test result, or who are unable or unwilling to take or abstinence measures approved by the investigator during the study.
  18. Participants who are considered not suitable for participating in a clinical trial by the investigator or the surgeon.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Arm 1: 4mg/kg amogammadex sodium moderate antagonism

    Drug: Rocuronium (0.6mg/kg)

  • Experimental
    Arm 2: 8mg/kg amogammadex sodium moderate antagonism

    Drug: vecuronium bromide (0.1mg/kg)

  • Experimental
    Arm 3: 12mg/kg amogammadex sodium moderate antagonism

    Drug: vecuronium bromide (0.1mg/kg)

  • Experimental
    Arm 4: 16mg/kg amogammadex sodium moderate antagonism

    Drug: vecuronium bromide (0.1mg/kg)

  • Experimental
    Arm 5: 4mg/kg amogammadex sodium deep antagonism

    Drug: Rocuronium (0.6mg/kg)

  • Experimental
    Arm 6: 8mg/kg amogammadex sodium deep antagonism

    Drug: vecuronium bromide (0.1mg/kg)

  • Experimental
    Arm 7: 12mg/kg amogammadex sodium deep antagonism

    Drug: vecuronium bromide (0.1mg/kg)

  • Experimental
    Arm 8: 16mg/kg amogammadex sodium deep antagonism

    Drug: vecuronium bromide (0.1mg/kg)

Interventions

  • DrugRocuronium (0.6mg/kg)

    Drug page: Rocuronium

    a single-dose intravenous bolus of 0.6 mg/kg rocuronium bromide,additional 0.1-0.2 mg/kg can be provided based on the required depth of neuromuscular blockade for surgery.

  • Drugvecuronium bromide (0.1mg/kg)

    Drug page: Vecuronium

    A single-dose intravenous bolus of 0.10 mg/kg vecuronium bromide, additional 0.015 mg/kg can be provided based on the required depth of neuromuscular blockade for surgery.

06

What researchers measure

Primary outcomes

  1. Efficacy Evaluation: The time from the start of the administration of amogammadex sodium to the recovery of the TOFr to 0.9 on day 1.

    The TOFr value was measured using the TetraGraph neuromuscular transmission monitor during muscle relaxation monitoring. If The TOFr value is ≥ 0.9 for three consecutive times, the first time is recorded as the time of TOFr recovery to 0.9.

    Time frame: Time from the start of the administration of IP to the recovery of the TOFr to 0.9 on day 1

Secondary outcomes

  1. The Time from the start of administration of amogammadex sodium to recovery of the TOFr to 0.8 on day 1.

    The TOFr value was measured using the TetraGraph neuromuscular transmission monitor during muscle relaxation monitoring. If The TOFr value is ≥ 0.8 for three consecutive times, the first time is recorded as the time of TOFr recovery to 0.8.

    Time frame: Time from the start of administration of IP to recovery of the TOFr to 0.8 on day 1

  2. The Time from the start of administration of amogammadex sodium to recovery of the TOFr to 0.7 on day 1.

    The TOFr value was measured using the TetraGraph neuromuscular transmission monitor during muscle relaxation monitoring. If The TOFr value is ≥ 0.7 for three consecutive times, the first time is recorded as the time of TOFr recovery to 0.7.

    Time frame: Time from the start of administration of IP to recovery of the TOFr to 0.7 on day 1

Other outcomes

  1. Incidence of Adverse Events (AEs)

    Participant incidence of reported AEs as assessed by CTCAE v6.0 to determine the safety and tolerability of amogammadex sodium in participants undergoing elective surgery .

    Time frame: From amogammadex sodium dosing to post-surgery follow-up visit at day 8±1

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Jun 2027, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2026
First posted
May 19, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 30, 2027
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07595393
Lead sponsor
Amckaus PTY LTD.
Collaborators
Novotech (Australia) Pty Limited
Responsible party
Sponsor
First posted
May 19, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
May 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rocuronium · Vecuronium

Start the discussion